Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum

被引:56
作者
Eastman, RT
White, J
Hucke, O
Bauer, K
Yokoyama, K
Nallan, L
Chakrabarti, D
Verlinde, CLMJ
Gelb, MH
Rathod, PK
Van Voorhis, WC
机构
[1] Univ Washington, Dept Med, Seattle, WA 98195 USA
[2] Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA
[3] Univ Washington, Dept Biochem, Seattle, WA 98195 USA
[4] Univ Washington, Dept Chem, Seattle, WA 98195 USA
[5] Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA
关键词
D O I
10.1074/jbc.M413556200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The post-translational farnesylation of proteins serves to anchor a subset of intracellular proteins to membranes in eukaryotic organisms and also promotes protein-protein interactions. Inhibition of protein farnesyltransferase (PFT) is lethal to the pathogenic protozoa Plasmodium falciparum. Parasites were isolated that were resistant to BMS-388891, a tetrahydroquinoline (THQ) PFT inhibitor. Resistance was associated with a 12-fold decrease in drug susceptibility. Genotypic analysis revealed a single point mutation in the beta subunit in resistant parasites. The resultant tyrosine 837 to cysteine alteration in the beta subunit corresponded to the binding site for the THQ and peptide substrate. Biochemical analysis of Y837C-PFT demonstrated a 13-fold increase in BMS-388891 concentration necessary for inhibiting 50% of the enzyme activity. These data are consistent with PFT as the target of BMS-388891 in P. falciparum and suggest that PFT inhibitors should be combined with other antimalarial agents for effective therapy.
引用
收藏
页码:13554 / 13559
页数:6
相关论文
共 34 条
[1]   CENP-E as an essential component of the mitotic checkpoint in vitro [J].
Abrieu, A ;
Kahana, JA ;
Wood, KW ;
Cleveland, DW .
CELL, 2000, 102 (06) :817-826
[2]   Inhibitors of farnesyltransferase: A rational approach to cancer chemotherapy? [J].
Bell, IM .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (08) :1869-1878
[3]   Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from Trypanosoma cruzi and Leishmania major [J].
Buckner, FS ;
Eastman, RT ;
Nepomuceno-Silva, JL ;
Speelmon, EC ;
Myler, PJ ;
Van Voorhis, WC ;
Yokoyama, K .
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 2002, 122 (02) :181-188
[4]   Protein prenyl transferase activities of Plasmodium falciparum [J].
Chakrabarti, D ;
Azam, T ;
DelVecchio, C ;
Qiu, LB ;
Park, Y ;
Allen, CM .
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 1998, 94 (02) :175-184
[5]   Protein farnesyltransferase and protein prenylation in Plasmodium falciparum [J].
Chakrabarti, D ;
Da Silva, T ;
Barger, J ;
Paquette, S ;
Patel, H ;
Patterson, S ;
Allen, CM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (44) :42066-42073
[6]   A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors [J].
Del Villar, K ;
Urano, J ;
Guo, L ;
Tamanoi, F .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (38) :27010-27017
[7]   QUANTITATIVE ASSESSMENT OF ANTI-MALARIAL ACTIVITY INVITRO BY A SEMIAUTOMATED MICRODILUTION TECHNIQUE [J].
DESJARDINS, RE ;
CANFIELD, CJ ;
HAYNES, JD ;
CHULAY, JD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1979, 16 (06) :710-718
[8]   Protein farnesyltransferase: Structure and implications for substrate binding [J].
Dunten, P ;
Kammlott, U ;
Crowther, R ;
Weber, D ;
Palermo, R ;
Birktoft, J .
BIOCHEMISTRY, 1998, 37 (22) :7907-7912
[9]   Polyunsaturated fatty acids in lipid bilayers: Intrinsic and environmental contributions to their unique physical properties [J].
Feller, SE ;
Gawrisch, K ;
MacKerell, AD .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (02) :318-326
[10]   Farnesyl transferase inhibitors as anticancer agents [J].
Haluska, P ;
Dy, GK ;
Adjei, AA .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (13) :1685-1700